NEW YORK (
CHANGE IN RATINGS
was downgraded to Hold at TheStreet Ratings.
was upgraded at Goldman Sachs from Sell to Neutral. Valuation call, as the stock is down 19% over the past month, Goldman said.
Dana Holding Corp.
was initiated with a Buy rating at UBS. $16 price target. See limited downside at current levels, UBS said.
was initiated with a Market Perform rating at JMP Securities. Company is losing sales from Windows 8, JMP said.
was upgraded at Citigroup from Neutral to Buy. $49 price target. Company can potentially dominate hepC market with
Gilead Sciences was upgraded at BMO Capital Markets from Market Perform to Outperform. $49 price target. Pharmasset acquisition is a positive step toward longer term sustainable growth, BMO said.
Iconix Brand Group
was initiated with a Buy rating at Citigroup. $20 price target. No inventory, no manufacturing, and two-thirds of revenue guaranteed, Citigroup said.
was initiated with a Buy rating at ThinkEquity. $62 price target. Company can deliver double-digit sales growth in each of its core franchises, ThinkEquity said.
was initiated with a Hold rating at ThinkEquity. $26 price target. Company could face pricing pressure, given competition from non-PC devices.
was upgraded from Underperform to Buy at Needham. Valuation call, based on an $18 price target, Needham said.
was started with a Buy rating at Ticonderoga. $9 price target. Company has a more stable stream of management fees, Ticonderoga said.
was downgraded to Sell at TheStreet Ratings.
was initiated with an Overweight rating at JP Morgan. $72 price target. Company is carrying a lot of operating momentum into the new year, JP Morgan said.
was initiated with a Buy rating at Citigroup. $42 price target. Global secular growth story, Citigroup said.
was initiated with a Hold rating at Wunderlich. Valuation call, based on a $30 price target, Wunderlich said.
was downgraded at UBS from Buy to Neutral. $137 price target. Value captured with acquisition by Gilead, UBS said.
was upgraded at Brean Murray said. $48 price target. Company boosted its forecast, Brean Murray said.
STOCK COMMENTS / EPS CHANGES
estimates were lowered at Credit Suisse through 2012. Company is leveraged to weaker cyclical demand, Credit Suisse said. Neutral rating and $42 price target.
Analog Devices estimates were lowered at UBS through 2013. Results, outlook below estimates, UBS said. Maintain $38 price target and Buy rating.
Analog Devices numbers were lowered at Citigroup. Shares are now seen reaching $45. Estimates were also lowered on lower guidance and comparables, Citigroup said. Buy rating.
Analog Devices numbers were raised at Jefferies. Shares are now seen reaching $39, Jefferies said. Estimates were also raised on order stabilization. Hold rating.
numbers were raised at Morgan Stanley. Shares are now seen reaching $37. Estimates also increased. Underweight rating.
Amgen was downgraded at BMO Capital Markets from Outperform to Market Perform. $58 price target. Company is conducting a Dutch auction tender offer, BMO said.
Barnes & Noble
numbers were raised at Credit Suisse. Shares are now seen reaching $20. Estimates were also increased, as the company is nearing an inflection point, Credit Suisse said. Neutral rating.
estimates, target were increased at UBS. Shares are now seen reaching $5. Estimates were also increased on stronger profitability, UBS said. Neutral rating.
Brocade estimates were raised at Oppenheimer through 2012. Strong fourth quarter, Oppenheimer said. Perform rating.
Brocade estimates, target were increased at Goldman Sachs through 2013. Company boosted its guidance, Goldman said. Sell rating and new $4 price target.
numbers were lowered at Jefferies. Estimates were also lowered on limited opportunities for capital deployment, Jefferies said. Hold rating.
target was boosted at Guggenheim. Shares are now seen reaching $65. Company is managing risks and deserves a higher price multiple, Guggenheim said. Buy rating.
Gilead Sciences estimates and target were adjusted at UBS. Shares are now seen reaching $49. Estimates were lowered in the near term on acquisition, which is expected to ultimately be accretive, UBS said. Buy rating.
target was reduced at Goldman Sachs to $32. Company spun off its timeshare business, Goldman said. Neutral rating.
estimates and target were lowered at UBS. Shares are now seen reaching $75. Estimates were also lowered on increased streaming content spending, UBS said. Neutral rating.
Research In Motion
( RIMM) estimates were cut at Morgan Stanley through 2014. Survey suggests that less than half of current users are likely to upgrade, Morgan Stanley said. Equal-weight rating.
estimates were increased at Credit Suisse through 2013. Company is realizing higher chicken margins and paying a lower tax rate, Credit Suisse said. Neutral rating and $20 price target.
estimates were increased at UBS through 2013. Nonregulated operations drives beat, UBS said. Maintain $41 price target and Neutral rating.
were added to the U.S. Focus List at Credit Suisse. Company can deliver consistent double-digit annual earnings growth, Credit Suisse said. $64 price target.
>To submit a news tip, email:
and become a fan on
This article was written by a staff member of RealMoney.com.